What goes into selecting an ideal model for evaluating efficacy with immune-targeted therapies?

Watch as Dr. Eddie Wood discusses how the characteristics of the tumor underpin the establishment of a tumor microenvironment that governs the degree of responsiveness to therapy, and how this plays a role in model selection. You’ll learn how deep profiling by flow cytometry and gene expression analysis identifies molecular markers that reflect the response to therapy, and how these molecular changes may lead to the discovery of biomarkers of target engagement needed to simplify clinical development.


  • Eddie Wood, PhD, Senior Research Director, Charles River